TBAJ-876, a 3,5-Dialkoxypyridine Analogue of Bedaquiline, Is Active against Mycobacterium abscessus
Jickky Palmae Sarathy, Uday S. Ganapathy, Matthew Zimmerman, Véronique Dartois, Martin Gengenbacher, Thomas Dick
Abstract
Lung disease caused by Mycobacterium abscessus is very difficult to cure, and treatment failure rates are high. The antituberculosis drug bedaquiline (BDQ) is used as salvage therapy against this dreadful disease. However, BDQ is highly lipophilic, displays a long terminal half-life, and presents a cardiotoxicity liability associated with QT interval prolongation. Recent medicinal chemistry campaigns resulted in the discovery of 3,5-dialkoxypyridine analogues of BDQ which are less lipophilic, have higher clearance, and display lower cardiotoxic potential.
Topics & Concepts
BedaquilineMycobacterium abscessusIn vivoPharmacologyMedicineMycobacterium tuberculosisTuberculosisDrugAntibioticsMicrobiologyMycobacteriumBiologyPathologyBiotechnologyMycobacterium research and diagnosisTuberculosis Research and EpidemiologyInfectious Diseases and Mycology